Tyra Biosciences (NASDAQ:TYRA) Stock Price Target Raised at Wedbush

Tyra Biosciences (NASDAQ:TYRA) had its target price raised by Wedbush from $53.00 to $57.00 in a report published on Wednesday,Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other equities research analysts have also issued reports on TYRA. William Blair upgraded Tyra Biosciences to a “strong-buy” rating in a research note on Wednesday, September 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Thursday, October 15th. Jefferies Financial Group reissued a “buy” rating and set a $42.00 price target on shares of Tyra Biosciences in a research report on Wednesday, August 5th. Raymond James Financial restated a “strong-buy” rating and issued a $50.00 price target on shares of Tyra Biosciences in a report on Tuesday, October 6th. Finally, HC Wainwright decreased their price target on Tyra Biosciences from $29.00 to $27.00 and set a “buy” rating for the company in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $47.40.

Tyra Biosciences Price Performance

NASDAQ:TYRA opened at $20.97 on Wednesday. The business’s 50-day moving average is $21.95 and its two-hundred day moving average is $29.49. Tyra Biosciences has a 12 month low of $14.67 and a 12 month high of $40.65.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.07). As a group, equities research analysts predict that Tyra Biosciences will post -2.68 EPS for the current year.

Institutional Investors Weigh In On Tyra Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sterling Capital Management LLC lifted its holdings in Tyra Biosciences by 843.4% in the 3rd quarter. Sterling Capital Management LLC now owns 1,217 shares of the company’s stock worth $27,000 after buying an additional 1,088 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Tyra Biosciences by 15.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,889 shares of the company’s stock valued at $239,000 after buying an additional 1,424 shares during the last quarter. Public Employees Retirement System of Ohio boosted its position in Tyra Biosciences by 10.7% in the 1st quarter. Public Employees Retirement System of Ohio now owns 20,522 shares of the company’s stock valued at $786,000 after buying an additional 1,980 shares during the last quarter. State of Wyoming purchased a new position in Tyra Biosciences in the 2nd quarter valued at about $76,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Tyra Biosciences during the third quarter valued at about $67,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Key Stories Impacting Tyra Biosciences

Investors following TYRA have been watching these stories:

• Positive Sentiment: Wedbush raised its price target to $57 from $53 and maintained an Outperform rating, signaling increased analyst confidence. Wedbush price target update
• Neutral Sentiment: HC Wainwright lowered its price target to $27 from $29 but kept a Buy rating, a mixed signal on the stock’s prospects. HC Wainwright recommendations
• Negative Sentiment: Third-quarter EPS was a loss of $0.74, missing the consensus estimate of a $0.67 loss. The net loss widened to $51.1 million as research costs rose, which may weigh on sentiment despite the company’s funding cushion. Tyra Q3 loss widens

Tyra Biosciences Company Profile

Tyra Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges. The company’s pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.